サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1440017

がん免疫療法 - 世界市場の考察、競合情勢、市場予測（2030年）

Cancer Immunotherapy - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
がん免疫療法 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん免疫療法の市場規模は、2022年に852億3,000万米ドル、2030年までに1,628億7,000万米ドルに達し、2024年～2030年の予測期間にCAGRで11.63％の成長が見込まれます。市場は、世界のがんの有病率の上昇や、発がん性物質、喫煙、放射線、ウイルスなどへの曝露の増加などの要因により、楽観的な市場成長を示しています。さらに、医療支出の急増や、その他の治療法よりもがん免疫療法の採用が増加していることも、所定の予測期間において市場を牽引します。したがって、市場は2024年～2030年の予測期間に大幅なCAGRでの成長が推定されます。

がん免疫療法の市場力学

がん免疫療法市場を牽引する重要な特徴の1つは、世界中でのがんの有病率の上昇です。

例えば、世界保健機関（WHO）（2022）によると、2020年の乳がん罹患数は226万件、次いで肺がん221万件、大腸がん193万件、前立腺がん141万件、皮膚がん120万件、胃がん109万件となっています。また、欧州委員会のデータベースによれば、2020年の欧州における女性のがん罹患率は191万2,080人、男性は213万183人です。このように、世界中でがんの罹患率が増加していることから、今後数年間はがん免疫療法の需要が高まる見込みです。

さらに、喫煙、放射線被曝、特定の化学物質への曝露はすべて、がんのリスクの増大に関連しています。例えば、エプスタインバーウイルス、HIV、ヒトT細胞リンパ腫/白血病ウイルス感染は、リンパ腫や白血病を発症する危険因子です。したがって、上記の要因のいずれかにさらされる機会が増えれば、血液がんの患者数が増えることになります。同じように、上記の要因はあらゆる種類のがんのリスクを増加させ、結果としてがんの有病率を増加させ、それによって今後数年間にがん免疫療法の需要を増加させる可能性があります。

また、世界保健機関（WHO）（2022）によると、2020年に世界人口の22.3％がタバコを使用し、男性では全体の36.7％、女性では7.8％がタバコを使用していました。したがって、タバコの消費の増加はがんの有病率をさらに増加させ、最終的に所定の予測期間におけるがん免疫療法の需要を増加させます。

さらに、がん免疫療法の必要性に関する啓発活動の増加も、予測期間に市場の促進要因となることが見込まれます。

したがって、上記の要因が総合的に、2024年～2030年の予測期間にがん免疫療法市場全体を牽引します。

しかし、高い治療費や免疫療法治療の副作用などが、がん免疫療法市場の成長にとっての課題となる可能性があります。

COVID-19パンデミックは、がん免疫療法市場に若干の影響を与えています。パンデミックの発生は、がん、糖尿病、心血管疾患などの慢性疾患に対する外来受診のキャンセルや緊急性のない病院や処置の中止につながりました。その結果、がんやその他の上記の疾患の定期的な治療を目的とする患者が減少しました。しかし、COVID-19のワクチン開発は、ロックダウン規制の緩和と経済状況の正常化という経済回復のプロセスを生み出し、外来受診のような通常の医療サービスの再開のプロセスを開始し、それによってがん免疫療法市場における製品需要が軌道に乗りました。

がん免疫療法市場のセグメント分析

がん免疫療法市場のタイプセグメントでは、2023年にモノクローナル抗体セグメントが大きな収益シェアを占めると予測されています。これは主に、その他のタイプに比べてこのセグメントの優位性の輪が広いためでした。

モノクローナル抗体は、再現性と拡張性が高く、生産原料に制限がないため、世界中でもっとも一般的に処方されている免疫療法薬です。さらに、モノクローナル抗体はアッセイの感度と特異性をもたらします。

また、モノクローナル抗体は、がん細胞と細胞増殖を促進するタンパク質との結合を阻害します。これは、がんの増殖と生存に必要な活性であり、がん細胞に対する適切な治療法となります。

当レポートでは、世界のがん免疫療法市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 がん免疫療法市場レポートのイントロダクション

第2章 がん免疫療法市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 がん免疫療法市場の主な要因の分析

  • がん免疫療法市場の促進要因
  • がん免疫療法市場の抑制要因と課題
  • がん免疫療法市場の機会

第5章 がん免疫療法市場のポーターのファイブフォース分析

第6章 がん免疫療法市場に対するCOVID-19の影響の分析

第7章 がん免疫療法市場のレイアウト

  • タイプ別
    • モノクローナル抗体
    • 免疫調節剤
    • がんワクチン
    • チェックポイント阻害剤
    • その他
  • 適応症別
    • 肺がん
    • 乳がん
    • 前立腺がん
    • 大腸がん
  • エンドユーザー別
    • 病院、診療所
    • 専門センター
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 がん免疫療法市場の企業と製品のプロファイル

  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly and Co
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Gilead Sciences, Inc.
  • Dendreon Pharmaceuticals LLC.
  • Fate Therapeutics
  • Precision BioSciences
  • IOVANCE Biotherapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Sanofi
  • Mylan N.V.
  • Apotex Inc.
  • Hikma Pharmaceuticals PLC

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Cancer Immunotherapy Market
  • Table 3 Cancer Immunotherapy Market Analysis in Global (2021-2030)
  • Table 4 Cancer Immunotherapy Market Analysis in Global by Type (2021-2030)
  • Table 5 Cancer Immunotherapy Market Analysis in Global by Indication (2021-2030)
  • Table 6 Cancer Immunotherapy Market Analysis in Global by End-user (2021-2030)
  • Table 7 Cancer Immunotherapy Market Analysis in Global by Geography (2021-2030)
  • Table 8 Cancer Immunotherapy Market Analysis in North America (2021-2030)
  • Table 9 Cancer Immunotherapy Market Analysis in North America by Country (2021-2030)
  • Table 10 Cancer Immunotherapy Market Analysis in the US (2021-2030)
  • Table 11 Cancer Immunotherapy Market Analysis in Canada (2021-2030)
  • Table 12 Cancer Immunotherapy Market Analysis in Mexico (2021-2030)
  • Table 13 Cancer Immunotherapy Market Analysis in Europe (2021-2030)
  • Table 14 Cancer Immunotherapy Market Analysis in Europe by Country (2021-2030)
  • Table 15 Cancer Immunotherapy Market Analysis in France (2021-2030)
  • Table 16 Cancer Immunotherapy Market Analysis in Germany (2021-2030)
  • Table 17 Cancer Immunotherapy Market Analysis in the UK (2021-2030)
  • Table 18 Cancer Immunotherapy Market Analysis in Italy (2021-2030)
  • Table 19 Cancer Immunotherapy Market Analysis in Spain (2021-2030)
  • Table 20 Cancer Immunotherapy Market Analysis in Russia (2021-2030)
  • Table 21 Cancer Immunotherapy Market Analysis in Rest of Europe (2021-2030)
  • Table 22 Cancer Immunotherapy Market Analysis in Asia-Pacific (2021-2030)
  • Table 23 Cancer Immunotherapy Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 24 Cancer Immunotherapy Market Analysis in China (2021-2030)
  • Table 25 Cancer Immunotherapy Market Analysis in Japan (2021-2030)
  • Table 26 Cancer Immunotherapy Market Analysis in India (2021-2030)
  • Table 27 Cancer Immunotherapy Market Analysis in Australia (2021-2030)
  • Table 28 Cancer Immunotherapy Market Analysis in South Korea (2021-2030)
  • Table 29 Cancer Immunotherapy Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Table 30 Cancer Immunotherapy Market Analysis in Rest of World (2021-2030)
  • Table 31 Cancer Immunotherapy Market Analysis in Rest of World by Region (2021-2030)
  • Table 32 Cancer Immunotherapy Market Analysis in the Middle East (2021-2030)
  • Table 33 Cancer Immunotherapy Market Analysis in Africa (2021-2030)
  • Table 34 Cancer Immunotherapy Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Cancer Immunotherapy Market
  • Figure 3 Cancer Immunotherapy Market Analysis in Global (2021-2030)
  • Figure 4 Cancer Immunotherapy Market Analysis in Global by Type (2021-2030)
  • Figure 5 Cancer Immunotherapy Market Analysis in Global by Indication (2021-2030)
  • Figure 6 Cancer Immunotherapy Market Analysis in Global by End-user (2021-2030)
  • Figure 7 Cancer Immunotherapy Market Analysis in Global by Geography (2021-2030)
  • Figure 8 Cancer Immunotherapy Market Analysis in North America (2021-2030)
  • Figure 9 Cancer Immunotherapy Market Analysis in North America by Country (2021-2030)
  • Figure 10 Cancer Immunotherapy Market Analysis in the US (2021-2030)
  • Figure 11 Cancer Immunotherapy Market Analysis in Canada (2021-2030)
  • Figure 12 Cancer Immunotherapy Market Analysis in Mexico (2021-2030)
  • Figure 13 Cancer Immunotherapy Market Analysis in Europe (2021-2030)
  • Figure 14 Cancer Immunotherapy Market Analysis in Europe by Country (2021-2030)
  • Figure 15 Cancer Immunotherapy Market Analysis in France (2021-2030)
  • Figure 16 Cancer Immunotherapy Market Analysis in Germany (2021-2030)
  • Figure 17 Cancer Immunotherapy Market Analysis in the UK (2021-2030)
  • Figure 18 Cancer Immunotherapy Market Analysis in Italy (2021-2030)
  • Figure 19 Cancer Immunotherapy Market Analysis in Spain (2021-2030)
  • Figure 20 Cancer Immunotherapy Market Analysis in Russia (2021-2030)
  • Figure 21 Cancer Immunotherapy Market Analysis in Rest of Europe (2021-2030)
  • Figure 22 Cancer Immunotherapy Market Analysis in Asia-Pacific (2021-2030)
  • Figure 23 Cancer Immunotherapy Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 24 Cancer Immunotherapy Market Analysis in China (2021-2030)
  • Figure 25 Cancer Immunotherapy Market Analysis in Japan (2021-2030)
  • Figure 26 Cancer Immunotherapy Market Analysis in India (2021-2030)
  • Figure 27 Cancer Immunotherapy Market Analysis in Australia (2021-2030)
  • Figure 28 Cancer Immunotherapy Market Analysis in South Korea (2021-2030)
  • Figure 29 Cancer Immunotherapy Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Figure 30 Cancer Immunotherapy Market Analysis in Rest of World (2021-2030)
  • Figure 31 Cancer Immunotherapy Market Analysis in Rest of World by Region (2021-2030)
  • Figure 32 Cancer Immunotherapy Market Analysis in the Middle East (2021-2030)
  • Figure 33 Cancer Immunotherapy Market Analysis in Africa (2021-2030)
  • Figure 34 Cancer Immunotherapy Market Analysis in South America (2021-2030)
  • Figure 35 Market Drivers
  • Figure 36 Market Barriers
  • Figure 37 Market Opportunities
  • Figure 39 PORTER's Five Force Analysis
目次
Product Code: DISR0055

CANCER IMMUNOTHERAPY MARKET BY TYPE (MONOCLONAL ANTIBODIES, IMMUNOMODULATORS, CANCER VACCINES, CHECKPOINT INHIBITORS, AND OTHERS), BY INDICATION (LUNG CANCER, BREAST CANCER, PROSTATE CANCER, COLORECTAL CANCER, AND OTHERS), BY END-USER (HOSPITALS AND CLINICS, SPECIALTY CENTERS, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO RISE AT A SIGNIFICANT CAGR FORECAST till 2030 OWING TO THE ACCELERATING PREVALENCE OF CANCERS AND SURGING HEALTHCARE EXPENDITURE ACROSS THE GLOBE

The global cancer immunotherapy market is found to be 85.23 billion in 2022 and will grow at a CAGR of 11.63% during the forecast period from 2024 to 2030 in order to reach USD 162.87 billion by 2030. The cancer immunotherapy market is observing an optimistic market growth due to the factors such as the rising prevalence of cancer across the globe and the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and others. Further, the surging healthcare expenditure and the growing adoption of cancer immunotherapy over other treatment options will also drive the market of cancer immunotherapy market in the given forecast period. Therefore, the market for cancer immunotherapy is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

CANCER IMMUNOTHERAPY MARKET DYNAMICS:

One of the key aspect for driving the cancer immunotherapy market is the rising prevalence of cancers globally.

For instance, according to the World Health Organization (WHO) 2022, in 2020 the incidence of breast cancer was 2.26 million cases, followed by lung cancer -2.21 million cases, colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, skin cancer 1.20 million cases, and stomach cancer with 1.09 million cases, globally. Also, as per the database provided by the European Commission, the incidence of cancer among the women in Europe in 2020 was 1,912,080 and in males was 2,130,183. Thus, the increasing incidence of cancers across the globe will increase the demand of cancer immunotherapy in the upcoming years.

Further, smoking, radiation exposure, and exposure to certain chemicals have all been linked to the increased risk of cancers. For instance, Epstein-Barr virus, HIV and human T-cell lymphoma/leukemia virus infections are risk factors for developing lymphomas and leukemia. Thus, increased exposure to any of the above factor will increase the number of cases of blood cancer. In the same manner the above mentioned factors can increase the risk of any type of cancer, ultimately increasing the prevalence of cancer, thereby increasing the demand of cancer immunotherapy in the upcoming years.

Also, according to the World Health Organization (WHO) 2022, in 2020, 22.3% of the global population used tobacco, 36.7% of all men and 7.8% of the world's women. Thus, the increased consumption of tobacco will further increase the prevalence of cancers, ultimately increasing the demand of cancer immunotherapy in the given forecast period.

Additionally, increase in the awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period.

Therefore, the factors stated above collectively will drive the overall cancer immunotherapy market during the forecast period from 2024-2030.

However, high cost of the treatment, adverse effects of immunotherapy treatment, and others may prove to be challenging factors for cancer immunotherapy market growth.

The COVID-19 pandemic has slightly impacted the market for cancer immunotherapy. The outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitals and procedures for chronic disorders such as cancers, diabetes, cardiovascular disorders, others. This resulted in the reduced number of patients for the routine treatments of the cancer and other above mentioned disorders. However, vaccine development of COVID-19 has produced the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of regular healthcare services such as outpatient's visits, thereby bringing the demand for products on track in the cancer immunotherapy market.

CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS:

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines, Checkpoint Inhibitors, and Others), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, and Others), End-User (Hospitals and Clinics, Specialty Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the cancer immunotherapy market, the monoclonal antibodies segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the wider advantage circle of the segment as compared to the other type.

Monoclonal antibodies are the most commonly prescribed immunotherapeutic drugs across the globe as they are highly reproducible and scalable, and have unlimited production source. Moreover, the monoclonal antibodies offers sensitivity and specificity of assays.

Also, they block the connection between a cancer cell and proteins that promote cell growth, an activity that is necessary for cancer growth and survival, thereby making it an apt treatment for the cancer cells.

Further, the monoclonal antibodies are a type of targeted cancer therapy, which means they are designed to interact with specific targets. This property decreases the number of adverse events related with the therapy.

Also, the increasing investments in research & development of monoclonal antibodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened up new revenue streams for oncology therapeutics companies. These R&D efforts have resulted in the introduction of mAbs with properties such as adaptive immunity, antigen specificity, and antibody dependent cellular toxicity. Owing of their numerous advantages, mAbs are being used and researched for the treatment of various types of tumors.

Therefore, owing to the advantages and applications associated with the monoclonal antibodies, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global cancer immunotherapy market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL CANCER IMMUNOTHERAPY MARKET:

Among all the regions, the North America is expected to dominate the global cancer immunotherapy in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the increasing prevalence of cancers, the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and the presence of key market players in the region are factors which acts as a supportive factor for the North America cancer immunotherapy market growth.

According to the American Cancer Society 2022, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Also, according to the Canadian Centre for Applied Research in Cancer Control 2022, nearly 233,900 estimated cases will be reported in 2022, in Canada. Further, the global cancer observatory 2022, stated that the incidence of cancer in 2020 in Mexico was 195,499. Thus, from the above mentioned sources and statistics it can be concluded that the incidence of cancer is quite high in the North America, ultimately increasing the demand of cancer immunotherapy in the region.

Further, the increasing geriatric population in the region, increasing consumption of tobacco, alcohol, chemicals, and other carcinogenic substances, will surge the market of cancer immunotherapy market. For instance, according to the United Health Foundation 2022, more than 54 million adults ages 65 and older live in the United States, in 2022. Further, as per the U.S. Census Bureau 2022, the geriatric population accounts for about 16.5% of the nation's population. The source also stated that the number of older adults living in the United States is large and growing and is estimated that by 2050, the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million which is roughly 20% of the overall United States population. Thus, the increasing elderly population will increase the demand of cancer immunotherapy as the elderly patients have weak immune systems and are more prone cancers and other chronic disease.

Further, increasing ease of access to modern therapeutics, presence of key players, increasing healthcare expenditure, and others will also spur the market of cancer immunotherapy in the upcoming years.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the cancer immunotherapy market.

CANCER IMMUNOTHERAPY MARKET KEY PLAYERS:

Some of the key market players operating in the cancer immunotherapy market includes Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals LLC., Fate Therapeutics, Precision BioSciences, IOVANCE Biotherapeutics, Inc., Spectrum Pharmaceuticals, Inc., Sanofi, Mylan N.V., Apotex Inc., Hikma Pharmaceuticals PLC, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN CANCER IMMUNOTHERAPY MARKET:

In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration approved CARVYKTI, a cancer immunotherapy for the treatment of adults with relapsed or refractory multiple myeloma (RRMM).

In April 2022, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer as well as esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

KEY TAKEAWAYS FROM THE CANCER IMMUNOTHERAPY MARKET REPORT STUDY

  • Market size analysis for current cancer immunotherapy market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cancer Immunotherapy market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global cancer immunotherapy market.
  • Various opportunities available for the other competitor in the cancer immunotherapy market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current cancer immunotherapy market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for cancer immunotherapy market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS CANCER IMMUNOTHERAPY MARKET REPORT STUDY

  • Cancer immunotherapy products providers
  • Research organizations and consulting companies
  • Cancer immunotherapy -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in cancer immunotherapy
  • Various end users who want to know more about the cancer immunotherapy market and latest technological developments in the cancer immunotherapy market.

FREQUENTLY ASKED QUESTIONS FOR CANCER IMMUNOTHERAPY MARKET:

1. What is a cancer immunotherapy?

The cancer immunotherapy, also known as immuno-oncology, is a form of cancer treatment that uses the power of the body's own immune system to prevent, control, and eliminate cancer.

2. What is the global market for cancer immunotherapy?

The global cancer immunotherapy market is found to be 85.23 billion in 2022 and will grow at a CAGR of 11.63% during the forecast period from 2024 to 2030 in order to reach USD 162.87 billion by 2030.

3. What are the drivers for global cancer immunotherapy market?

The cancer immunotherapy market is witnessing a positive market growth owing to the factors such as the rising prevalence of cancer across the globe and the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and others will increase the demand of cancer immunotherapy in the market. Further, the surging healthcare expenditure and the growing adoption of cancer immunotherapy over other treatment options will also drive the market of cancer immunotherapy market in the given forecast period.

4. Who are the key players operating in the global cancer immunotherapy market?

Some of the key market players operating in the cancer immunotherapy market includes Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals LLC., Fate Therapeutics, Precision BioSciences, IOVANCE Biotherapeutics, Inc., Spectrum Pharmaceuticals, Inc., Sanofi, Mylan N.V., Apotex Inc., Hikma Pharmaceuticals PLC, and others.

5. Which region has the highest share in cancer immunotherapy market?

Among all the regions, North America is estimated to hold the significant revenue share in the global cancer immunotherapy market. This can be ascribed to the increasing prevalence of cancers in the region, the increasing exposure to carcinogenic substances, smoking, radiation, viruses, and the presence of key market players in the region are factors which acts as a supportive factor for the North America cancer immunotherapy market growth.

Table of Contents

1. Cancer Immunotherapy Market Report Introduction

2. Cancer Immunotherapy Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment

3. Regulatory Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Cancer Immunotherapy Market Key Factors Analysis

  • 4.1 Cancer Immunotherapy Market Drivers
    • 4.1.1 The rising prevalence of cancer across the globe
    • 4.1.2 Increasing exposure to carcinogenic substances, smoking, radiation, viruses, and others
    • 4.1.3 Growing Adoption of Cancer Immunotherapy over Other Treatment Options
    • 4.1.4 Surge in healthcare expenditure
  • 4.2 Cancer Immunotherapy Market Restraints and Challenges
    • 4.2.1 High Cost of Treatment
    • 4.2.2 Adverse Effects of Immunotherapy Treatment
  • 4.3 Cancer Immunotherapy Market Opportunities
    • 4.3.1 Development of Bioinformatics Tools and Targeted Therapy
    • 4.3.2 Growing awareness regarding proper treatment and management of cancers

5. Cancer Immunotherapy Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Cancer Immunotherapy Market

7. Cancer Immunotherapy Market Layout

  • 7.1 By Type
    • 7.1.1 Monoclonal Antibodies
    • 7.1.2 Immunomodulators
    • 7.1.3 Cancer Vaccines
    • 7.1.4 Checkpoint Inhibitors
    • 7.1.5 Others
  • 7.2 By Indication
    • 7.2.1 Lung Cancer
    • 7.2.2 Breast Cancer
    • 7.2.3 Prostate Cancer
    • 7.2.4 Colorectal Cancer
    • 7.2.5 Others
  • 7.3 By End-User
    • 7.3.1 Hospitals and Clinics
    • 7.3.2 Specialty Centers
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.1.2 Canada Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.1.3 Mexico Cancer Immunotherapy Market in USD million (2021-2030)
    • 7.4.2 Europe
      • 7.4.2.1 France Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.2 Germany Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.3 United Kingdom Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.4 Italy Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.5.2.5 Spain Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.6 Russia Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.2.7 Rest of Europe Cancer Immunotherapy Market in USD million (2021-2030)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.2 Japan Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.3 India Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.4 Australia Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.5 South Korea Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.3.6 Rest of Asia Pacific Cancer Immunotherapy Market in USD million (2021-2030)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1. Middle East Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.4.2 Africa Cancer Immunotherapy Market in USD million (2021-2030)
      • 7.4.4.3 South America Cancer Immunotherapy Market in USD million (2021-2030)

8. Cancer Immunotherapy Market Company and Product Profiles

  • 8.1 Amgen Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 AstraZeneca
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 F. Hoffmann-La Roche Ltd
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Bayer AG
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 Bristol-Myers Squibb
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5. Entropy
  • 8.6 Eli Lilly and Co
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy
  • 8.7 Merck & Co., Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5. Entropy
  • 8.8 Novartis AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5. Entropy
  • 8.9 Pfizer Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10 Johnson & Johnson Services, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5. Entropy
  • 8.11 Gilead Sciences, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5. Entropy
  • 8.12 Dendreon Pharmaceuticals LLC.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5. Entropy
  • 8.13 Fate Therapeutics
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5. Entropy
  • 8.14 Precision BioSciences
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5. Entropy
  • 8.15 IOVANCE Biotherapeutics, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5. Entropy
  • 8.16 Spectrum Pharmaceuticals, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5. Entropy
  • 8.17 Sanofi
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5. Entropy
  • 8.18 Mylan N.V.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5. Entropy
  • 8.19 Apotex Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5. Entropy
  • 8.20 Hikma Pharmaceuticals PLC
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us